Aeterna Zentaris Announces Expiration of Remaining Series B Warrants

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”) today announced that the remaining 8,064 Series B Common Share Purchase Warrants (the “Series B Warrants”) issued in connection with the Company’s March 2015 financing expired on September 12, 2016 without being exercised. The Company had 9,939,863 Common Shares issued and outstanding as of the close of business on September 13, 2016.

David A. Dodd, President and Chief Executive Officer of the Company, explained, “All Series B Warrants issued in connection with our March 2015 financing have now been extinguished. Therefore, there will be no further dilution of our shareholders as a result of the Series B Warrants. I am pleased that we can report that the repair of our capital structure is now complete. We are looking forward to the impending completion of the pivotal, Phase III trials for Macrilen™ and Zoptrex™ and to the submission of NDAs for the products, if the results of the trials warrant doing so.”

About Aeterna Zentaris Inc.

Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health. We are engaged in drug development activities and in the promotion of products for others. We are now conducting Phase 3 studies of two internally developed compounds: Macrilen™ and Zoptrex™. The focus of our business development efforts is the acquisition of licenses to products that are relevant to our therapeutic areas of focus. We also intend to license out certain commercial rights of internally developed products to licensees in territories where such out-licensing would enable us to ensure development, registration and launch of our product candidates. Our goal is to become a growth-oriented specialty biopharmaceutical company by pursuing successful development and commercialization of our product portfolio, achieving successful commercial presence and growth, while consistently delivering value to our shareholders, employees and the medical providers and patients who will benefit from our products. For more information, visit www.aezsinc.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160914005365/en/

Aeterna Zentaris Inc.Philip A. Theodore, 843-900-3223Senior Vice Presidentir@aezsinc.com

Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Mar 2024 to Apr 2024